Endocarditis Prophylaxis in Patients with History of Rheumatic Fever

Current Recommendations for Endocarditis Prophylaxis

The American Heart Association recommends that endocarditis prophylaxis is not routinely indicated for most patients with rheumatic heart disease, unless they have prosthetic valves or prosthetic material used in valve repair, based on guidelines from the American Heart Association 1, 2
The American Heart Association guidelines indicate that prophylaxis is only recommended for high-risk patients with rheumatic heart disease who have prosthetic cardiac valves, prosthetic material used in valve repair, previous history of infective endocarditis, or are cardiac transplant recipients who develop cardiac valvulopathy 1, 2

For patients already receiving penicillin prophylaxis for rheumatic fever who require endocarditis prophylaxis for dental procedures, the American Heart Association recommends using an agent other than penicillin, due to the likelihood of oral α-hemolytic streptococci developing resistance to penicillin in these patients 1, 2

The American Heart Association recommends intramuscular benzathine penicillin G as first-line prophylaxis for rheumatic fever, with a dosage of 1.2 million units every 4 weeks, or every 3 weeks in high-incidence populations or for patients with recurrences despite adherence 1, 3, 4
For penicillin-allergic patients, the American Heart Association suggests alternative options such as oral penicillin V, sulfadiazine, or erythromycin/clarithromycin 1, 2

The American Heart Association recommends that the duration of prophylaxis for patients with carditis and persistent valvular disease should be 10 years after last attack or until age 40, whichever is longer, based on guidelines from the American Heart Association and European Society of Cardiology 4, 5

Maintaining optimal oral health care is crucial for patients with rheumatic heart disease to reduce the risk of healthcare-associated infective endocarditis, as emphasized by the American Heart Association and European Society of Cardiology 1, 2, 5

The American Heart Association advises against assuming all rheumatic heart disease patients need endocarditis prophylaxis, as current guidelines have significantly narrowed indications, and against using penicillin for dental procedure prophylaxis in patients already on penicillin prophylaxis for rheumatic fever 1, 2

The recommendation against routine endocarditis prophylaxis for rheumatic heart disease is based on a lack of published evidence supporting its efficacy, with a strength of evidence classified as low, according to the American Heart Association 1, 2
The evidence for secondary prophylaxis of rheumatic fever using benzathine penicillin G is strong, with a Class I, LOE A recommendation from the American Heart Association 1, 3